ANVS Earnings & Financial Statements
Annovis Bio, Inc.
$1.02
-$0.04(-3.77%)
21
Overall
40
Value
10
Tech
15
Quality
Market Cap
$43.53M
Volume
843.70K
52W Range
$1.04 - $5.50
Target Price
$10.50
ANVS earnings and financial statements: Annovis Bio, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ANVS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$29.70M | -$26.70M | -$45.00M | -$25.51M | -$14.54M |
| EBITDA | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -$14.49M |
| Net income | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -$14.49M |
| EPS (diluted) | $-1.40 | $-2.31 | $-6.23 | $-3.10 | $-1.90 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $21.08M | $13.93M | $10.21M | $36.02M | $46.00M |
| Total liabilities | $4.23M | $4.62M | $17.96M | $7.70M | $1.51M |
| Shareholders’ equity | $16.85M | $9.31M | -$7.75M | $28.32M | $44.49M |
| Cash and equivalents | $19.50M | $10.55M | $5.75M | $28.38M | $45.69M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -$9.13M |
| Free cash flow | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -$9.13M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANVS | $1.02 | -3.8% | 843.70K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |